




Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study

This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease

Antoni Sicras-Mainar ¹
Francisco J de Abajo ^{2,3}
José Luis Izquierdo-
Alonso ^{4,5}

¹Health Economics & Outcomes Research, Atrys Health, Barcelona, Spain; ²Unidad de Farmacología Clínica, Hospital Universitario Príncipe de Asturias, Madrid, Spain; ³Departamento de Ciencias Biomédicas, Universidad de Alcalá (IRYCIS), Madrid, Spain; ⁴Departamento de Medicina y Especialidades, Universidad de Alcalá, Madrid, Spain; ⁵Servicio de Neumología, Hospital Universitario de Guadalajara, Guadalajara, Spain

Objective: To determine the clinical and economic consequences of inhaled corticosteroid doses and particle size in patients on triple-inhalation therapy for COPD.

Methods: Patients aged ≥ 40 years who initiated treatment with multi-inhaler triple-inhaled therapy between 1 January 2015 and 31 March were included and followed for 1 year. Patients were grouped according to inhaled corticosteroid (ICS) dose (low/medium/high) and particle size device (extrafine/non-extrafine particles). Outcome variables were moderate and severe exacerbations, pneumonia and healthcare resource use (HCRU) costs. A multivariate analysis was performed for model correction ($p < 0.05$).

Results: A total of 2185 patients (mean age 72.3 years, 82.9% male) were analysed. Of these, 849 (38.9%) patients received low-dose ICS, 612 medium-dose ICS (28.0%) and 724 (33.1%) high-dose ICS. Exacerbations occurred more frequently with increasing IC dose (low: 26.4%, medium: 28.7% and high: 30.4%; $p = 0.047$), as did the proportion of pneumonia (3.4%, 4.2% and 6.9%, respectively ($p = 0.041$)). The annual mean cost/unit was € 2383 for low dose, € 2401 for medium dose and € 2625 for high dose ($p = 0.024$). Four hundred and sixty-two (31.6%) patients used an extrafine particle device and 999 (68.4%) a non-extrafine particle device: the proportion of exacerbations was 24.0% vs 30.4% ($p = 0.012$), and the annual mean cost/unit was € 2090 vs € 2513, respectively ($p < 0.001$). The number of exacerbations was directly correlated with FEV₁ ($\beta = -0.157$), age ($\beta = 0.071$), Charlson index ($\beta = 0.050$) and device type (extrafine: $\beta = 0.049$) ($p < 0.02$).

Conclusion: In patients with COPD receiving multi-inhaler triple therapy, higher ICS doses were not associated with a further reduction in exacerbations, whereas we found an increased risk of pneumonia. The use of inhaler devices delivering extrafine ICS particle was associated with a lower rate of exacerbations, resulting in lower overall HCRU costs.

Keywords: COPD, triple-therapy, extrafine particle, exacerbations, pneumonia, health costs

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by progressive, difficult-to-reverse, chronic limitation of the airflow¹ that is associated with an abnormal inflammatory lung response to harmful particles or gases, especially tobacco, with significant systemic repercussions.^{1,2} Around the world, COPD is an increasingly prevalent disease,^{3,4} with a prevalence of 6–10.4% estimated in Spain, among people aged 40–80 years.⁴ COPD is a public health problem as it is the fourth leading cause of death worldwide, and one of the leading causes of morbidity, occupational disability, and worsened quality of life.^{1,2} COPD results in

Correspondence: Antoni Sicras-Mainar
Atrys Health SA, C/Provença 392, bajos,
Barcelona 08025 Spain
Tel +34 934 934 581 561
Email ansicras@atryshealth.com

high healthcare costs, with the most severe patients and COPD exacerbations consuming the most resources.^{1–3} In Spain, the direct mean cost per patient with COPD is estimated at €1712–3238/year, 50–70% of which are in hospital costs.^{5–7}

Maintenance pharmacotherapy for COPD is based on long-acting bronchodilators as the first line of treatment with long-acting beta adrenergic [LABA] and/or long-acting anticholinergics [LAMA]. LABA in combination with inhaled corticosteroid (ICS) is reserved for patients with frequent exacerbations and/or a mixed COPD-asthma phenotype, regardless of the level of functional severity,^{1,8,9} and triple therapy with LAMA-LABA-ICS can be a potentially effective treatment in this group of patients as well.^{2,9} The TRILOGY¹⁰ and FULFIL¹¹ clinical trials highlighted the superiority of the combination of the three drugs in patients with severe COPD over the use of IC/LABA alone. In clinical practice, the use of ICS in COPD is controversial (balance between efficacy and safety [pneumonia]), with arguments both for and against their use, and only in combination with an LABD.¹² The WISDOM study^{13,14} found no increased risk of adverse effects in triple therapy compared with dual bronchodilation (LABA/LAMA). However, the benefit–risk ratio of ICS-containing therapy may depend on several factors, including the ICS molecule characteristics (potency, lipophilicity), dose, and particle size.^{9,12} There seems to be some consensus on the use of medium-low dose ICS in patients with the COPD-asthma phenotype and in frequent exacerbators.¹²

Particle size is the major determinant in the deposition and distribution of inhaled drug within the lungs and hence is related to local efficacy. The particle size distribution of an aerosol is usually expressed in terms of its mass median aerodynamic diameter (MMAD). To reach the lower respiratory tract past the carina, the MMAD of inhaled particles should be less than 5 µm in diameter; specifically, the particle size with the most efficient deposition in the small airways, so-called extrafine particle fraction, is said to be less than 2 µm.¹⁵ The literature reviewed does not usually differentiate between the type of particles (extrafine vs non-extrafine/fine) contained in inhalers used for treating COPD.¹⁶ While most ICS are fine particles with an MMAD of 2–4 microns, some presentations use extrafine particles (approximate diameter of 1 micron). Some authors suggest there may be better effectiveness and clinical safety with the use of extrafine particle devices for the treatment of COPD,^{17,18} but there is very little data on their impact in normal clinical

practice. In addition, evidence on the healthcare resource use and associated costs in this patient group is limited. The objective of the study was to determine the clinical (exacerbations and pneumonia) and economic consequences (healthcare resource use and costs) of the use of different doses of inhaled corticosteroids (high/medium/low) and their particle size (extrafine vs non-extrafine) in multi-inhaler triple inhalation therapy for COPD.

Patients and Methods

Design and Study Population

An observational, multicentre, longitudinal retrospective study was carried out using a before/after design with a control group, made by review of computerized medical records. The study population was obtained from the records of health providers from various centres in Spain (unified in the dissociated BIG-PAC[®] database; Real Life Data; <http://www.encepp.eu/encepp/search.htm>). The medical records come from different primary care centers and hospitals (integrated areas) from seven Autonomous Communities of the Spanish territory (computerized medical records, 1.9 million patients). Data are subject to rigorous validation and recoding (anonymized/dissociated data) and are then exported to the BIG-PAC[®] database. The population assigned to the participating centres is mostly urban with medium-low socioeconomic status.

Inclusion and Exclusion Criteria

Patients who sought care and initiated treatment with multi-inhaler triple therapy (LAMA-LABA-ICS) between 1 January 2015 and 31 March 2017 were included in the study. Inclusion criteria were: (a) age ≥40 years, (b) date of diagnosis of COPD ≥ 12 months before the index date, (c) inclusion in the prescription programme for obtaining medical prescriptions (with a recorded daily dose, time interval and duration of each treatment administered, and two or more prescriptions), (d) guaranteed regular monitoring (two health records in the computer system) and (e) ≥6 months on treatment with triple therapy. Exclusion criteria were (a) transfer out to other centres, displaced or out-of-area, (b) permanent institutionalization, and (c) a history of pulmonary emphysema, bronchiectasis, cystic fibrosis and/or bronchial neoplasm.

Study Groups and Follow-Up Period

Patients were differentiated according to: 1) ICS dose: a) low dose, b) medium dose and c) high dose; and 2) ICS

particle size: a) extrafine particle (EFP) (Modulite[®], NextHaler[®]) and b) non-extrafine particle (nEFP). Patients were classified in ICS dose groups following the Bassan¹⁸ criteria according to the initial prescription regimen (Supplementary Table 2). The follow-up period was 1 year from the index date. Analysis of the ICS-containing inhalers excluded patients receiving high doses of ICS (N=724), as patients were not receiving high doses of ICS in extrafine particle devices for comparison.¹⁸

Definition of COPD, Exacerbation, and Pneumonia

Records of patients with COPD were obtained using the International Classification of Diseases (ninth edition) Clinical Modification (ICD-9-MC; codes 491, 492 and/or 496 for COPD and/or exacerbations) or their ICD-10 equivalents (codes: J41, J42, J44). The physician's judgement was the criteria followed. However, confirmation of the COPD diagnosis required the recording of no significant reversibility airflow obstruction following bronchodilator administration according to forced spirometry and the forced volume in the first second (FEV₁/forced vital capacity ratio < 70% in the stable phase). The Global Initiative for Obstructive Lung Disease (GOLD)⁸ guidelines, which define an exacerbation as an event in the natural course of the disease characterized by a change in patient's baseline dyspnoea, cough and/or sputum that goes beyond daily variations, which is acute in its onset, and may require a change in regular medication (sustained aggravation of the baseline situation). In this respect, two types of exacerbations were considered: (a) severe: those requiring hospital admission, and (b) moderate: those requiring treatment with antibiotics and/or oral corticosteroids. For each exacerbation, blood eosinophil levels and the time from diagnosis (in years) were obtained. In addition, lung function (FEV₁) and the functional severity of COPD (classification) were also obtained according to GOLD⁸ recommendations. Additionally, the records of patients with pneumonia were obtained using ICD-9-MC; codes 482–486, or their equivalents, according to ICD10: J12–J18.

Sociodemographic and Comorbidity Variables

Sociodemographic and comorbidity variables recorded were age (continuous and by intervals), sex, and the history of hypertension, diabetes, dyslipidaemia, obesity (BMI 30 kg/m²), active smoking, ischemic heart disease,

stroke, heart failure and other conditions (Table 1). As a summary variable of general comorbidity, a) the Charlson comorbidity index¹⁹ and b) the number of chronic comorbidities were collected for each patient.

Description of Treatment

The medications indicated for the treatment of COPD were obtained according to the Anatomical Therapeutic Chemical Classification System (ATC):²⁰ oral corticosteroids (OCS, H02AB), IC/LABA (R03AK), beta-2 short-acting agonists (SABA, R03AC), short-acting muscarinic antagonist or anticholinergics (SAMA, R03BB), LAMA (R03BB), xanthines (R03DA and R03DB), leukotriene receptor antagonists (R03DC), and home oxygen. In addition, patients who received treatment with long-acting oral/systemic corticosteroids (chronic schedule) were differentiated from those who received them only for the control of an exacerbation. The duration of ICS treatment was calculated as the difference in dates between the initial prescription (index date) and the final prescription (last available prescription), in months (during the follow-up period). In addition, a treatment change was considered when there was a modification of any of the three molecules (ICS, LAMA, LABA), with respect to the baseline situation. A change in treatment was not considered when there was a variation in the dose or the type of device used.

Healthcare Resource Use

Direct health costs related to care (medical visits, days of hospitalization, emergency visits, diagnostic or therapeutic requests and medication) provided by professionals were collected. Costs were expressed at the mean cost per patient per year (mean PPY). The study concepts and their costs in € 2018 are shown in Supplementary Table 1. The cost of prescriptions for each medication was quantified according to the retail price per pack at the time of prescription.

Ethical and Legal Aspects

Clinical records in the BIG-PAC database are fully anonymised, and researchers do not have access to patients' personal data. When the information used does not contain personal data, Spanish law exempts studies from evaluation by a Research Ethics Committee.

Statistical Analysis

Data were validated to ensure the quality of the records. A descriptive-univariate statistical analysis was made.

Qualitative data were expressed as absolute and relative frequencies and quantitative data as means and standard deviation or medians and interquartile ranges. The 95% confidence intervals (CI) used to estimate parameters were based on the total number of subjects without missing values. The normality of distribution was tested using the Kolmogorov–

Smirnov test. In the bivariate analysis, ANOVA, the chi-square and Pearson's linear correlation tests were used.

The multivariate models used were (a) covariance analysis (ANCOVA; procedure: estimation of marginal means; Bonferroni's adjustment) for correction of resource use (dependent variable, according to patient classification),

Table 1 Baseline Characteristics of Study Subjects, COPD Classification and Medication Administered During Follow-Up by Study Groups

Inhaled ICS Doses	Low	Medium	High	Total	p
Number of Patients, %	N=849 (38.9%)	N=612 (28.0%)	N=724 (33.1%)	N=2185 (100%)	
Sociodemographic features					
Mean age, years	71.6 (11.8)	72.5 (11.4)	72.8 (10.5)	72.3 (11.3)	0.094
Age Range, years					
40–64	27.3%	23.5%	21.3%	24.3%	
65–74	29.2%	28.9%	29.0%	29.1%	
≥ 75	43.5%	47.5%	49.7%	46.7%	0.049
Sex (male)	80.7%	82.4%	80.4%	81.1%	0.619
Overall comorbidity					
Mean of diagnoses	3.6 (1.9)	3.7 (1.9)	3.7 (1.9)	3.7 (1.9)	0.413
Mean Charlson Index	1.6 (1.5)	1.8 (1.5)	1.7 (1.5)	1.7 (1.5)	0.332
1	32.0%	30.4%	30.7%	31.1%	
2	19.1%	21.4%	19.3%	19.8%	
3+	24.6%	26.5%	27.5%	26.1%	0.334
Associated comorbidities					
Hypertension	60.1%	61.6%	61.9%	61.1%	0.731
Diabetes mellitus	26.3%	28.1%	27.1%	27.0%	0.737
Dyslipidaemia	55.0%	51.1%	55.1%	54.0%	0.258
Obesity	33.7%	33.5%	34.0%	33.7%	0.982
Active smoker	23.1%	23.2%	21.0%	22.4%	0.528
Ischemic heart disease	16.5%	19.8%	17.8%	17.8%	0.271
Cerebrovascular accident	11.2%	13.1%	11.0%	11.7%	0.443
Heart failure	23.2%	27.1%	24.0%	24.6%	0.210
Kidney failure	10.5%	11.3%	11.6%	11.1%	0.767
Depressive syndrome	13.3%	15.2%	13.3%	13.8%	0.509
Malign neoplasm	14.1%	14.2%	15.3%	14.6%	0.768
Asthma	13.0%	11.4%	12.7%	12.4%	0.664
COPD Severity					
GOLD II (moderate)	64.8%	57.8%	59.7%	61.1%	
GOLD III (severe)	34.0%	37.2%	42.8%	37.0%	
GOLD IV (very severe)	1.2%	2.0%	2.5%	1.8%	0.029
Other parameters/variables					
Time from diagnosis, years	15.3 (6.4)	15.9 (6.0)	16.3 (5.8)	15.8 (6.1)	0.011
BMI, kg/m ²	29.1 (5.2)	29.1 (5.0)	28.7 (4.8)	29.0 (5.0)	0.229
FEV ₁ , %	60.7 (13.2)	58.6 (13.5)	54.9 (14.3)	58.2 (13.9)	<0.001
Blood eosinophils, cells/μL	185 (112)	186 (125)	182 (103)	184 (119)	0.527
Mean ICS dose	284.5 (83.1)	475.5 (67.1)	986.7 (121.5)	570.7 (317.1)	0.001

Notes: Values expressed as percentage or mean (SD: standard deviation), p: statistical significance.

Abbreviations: ICS, inhaled corticosteroids; GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index, kg/m²; FEV₁, forced expiratory volume in the first second.

and (b) multiple linear regression to determine variables associated with health costs and exacerbations (procedure: consecutive steps). The covariates included in the models were age, sex, FEV₁, the Charlson index and time from diagnosis. Statistical significance was established as $p < 0.05$. The analysis was made using SPSSWIN version 23.

Results

Of an initial population of 1.9 million, 802,237 patients aged ≥ 40 years received care between 1 January 2015 and 31 March 2017. Of these, 13,690 patients were diagnosed with COPD. Finally, 2185 patients who met the inclusion/exclusion criteria were analysed and followed during the study period (Figure 1).

Results According to ICS Dose

Table 1 shows the general characteristics of patients according to study groups: 849 patients received low-dose ICS (38.9%), 612 received medium-dose ICS (28.0%) and 724 received high-dose ICS (33.1%). The distribution of ICS dose according to the different drug combinations (number of patients) is detailed in Supplementary Table S3. The mean age was 72.3 years and 81.1% were male. Hypertension (61.1%), dyslipidaemia (54%), obesity (33.7%) and diabetes (27%) were the most frequent comorbidities. There was acceptable comparability between the ICS dose groups with respect to sociodemographic characteristics and associated comorbidities.

Table 2 shows the main complications (exacerbations and pneumonia) according to the ICS dose. Total exacerbations increased from baseline with increasing dose of ICS (low: 26.4%, medium: 28.7% and high: 30.4% ($p=0.047$)). Both moderate (26.2%, 28.9% and 29.1% ($p=0.044$)) and severe exacerbations (6.7%, 9.2% and 11.2% ($p=0.014$)) were higher in patients on high-dose IC. The mean time to first exacerbation was significantly shorter in patients taking high doses of ICS (132, 130 and 116 days, respectively ($p < 0.05$)) (Table 2). Significant associations were also observed between high doses and the functional severity of COPD (in severe COPD; low: 34%, medium: 37.2%, and high: 42.8% ($p=0.029$)), as well as between ICS dose and use of oral corticosteroids (low: 21.8%, medium: 23.5% and high: 26.4% ($p < 0.001$)) and % FEV₁ (low: 60.7%; medium: 58.6% and high: 54.9% ($p < 0.001$)) (Table 2).

The proportion of pneumonia (patients) increased with the ICS dose (low: 3.4%, medium: 4.2% and high: 6.9% ($p=0.041$)). Total healthcare costs were € 5.3 million, of which 66.1% were in primary healthcare and 33.9% in specialized care. The biggest cost components were hospital admissions (9.8%), primary healthcare visits (14%) and medication (48.7%). The annual mean PPPY cost (corrected for covariates, ANCOVA) was higher with increasing dose of ICS (low: € 2383, medium: € 2401 and high: € 2625 ($p=0.024$)) (difference between high-/low-dose ICS: € 242/patient/year) (Table 3).




Figure 1 Study flow diagram. A retrospective observational study was carried out, made from the review of medical records (computerized databases, with anonymised and dissociated data) of patients diagnosed with COPD.

Abbreviation: ICS, inhaled corticosteroid.

Results According to ICS Particle Size

Table 4 shows general patient characteristics according to the particle size (subjects with high doses of ICS were excluded): 462 patients (31.6%) received treatment with an EFP ICS/LABA, and 999 with an nEFP ICS/LABA (68.4%). In general, the baseline characteristics were comparable between the groups analysed. Patients using EFP, compared with nEFP, had similar functional COPD severity (GOLD III: 37% vs 36.4%; $p=0.861$), oral

corticosteroid use (26.4% vs 25.3%, $p=0.413$) and FEV₁ (59.3% vs 60.1%; $p=0.269$).

Table 5 shows the proportion of exacerbations and pneumonia according to the ICS particle size. Total exacerbations were lower for EFP vs nEFP (24% vs 30.4%; $p=0.012$). Moderate exacerbations were also lower for EFP vs nEFP (23.6% vs 29.9%; $p=0.048$), while serious exacerbations (hospital admissions: 6.5% vs 8.3%; $p=0.078$) did not differ significantly. No relevant

Table 2 Incidence of Exacerbations and Pneumonia According to Inhaled Corticosteroid (ICS) Dose

Inhaled ICS Doses	Low	Medium	High	Total	p
Number of Patients	N=849	N=612	N=724	N=2185	
Follow-up period (one year)					
Mean (SD) number of exacerbations	0.5 (1.0)	0.6 (1.2)	0.6 (1.2)	0.6 (1.1)	0.062
% Patients with 0 exacerbation	72.6%	70.3%	69.6%	70.9%	
% Patients with ≥ 1 exacerbation	26.4%	28.7%	30.4%	29.0%	0.047
1	16.5%	16.7%	18.4%	17.2%	
2	6.1%	4.4%	4.6%	5.1%	
3+	4.8%	8.7%	7.5%	6.8%	0.024
Mean nb (SD) number of mod exacerbation	0.4 (0.8)	0.5 (0.9)	0.5 (1.0)	0.4 (0.9)	0.257
% Patients with 0 mod exacerbation	72.8%	71.1%	70.9%	71.7%	
% Patients with ≥ 1 mod exacerbation	26.2%	28.9%	29.1%	28.3%	0.044
1	19.4%	19.0%	21.3%	19.9%	
2	3.8%	4.1%	1.7%	3.2%	
3+	4.0%	5.9%	6.2%	5.3%	0.149
Mean nb (SD) of severe exacerbation	0.1 (0.3)	0.1 (0.4)	0.1 (0.4)	0.1 (0.4)	0.003
% Patients with 0 severe exacerbation	93.3%	90.8%	88.8%	91.1%	
% Patients with ≥ 1 severe exacerbation	6.7%	9.2%	11.2%	8.9%	0.014
1	6.0%	7.2%	8.8%	7.3%	
2	0.7%	2.0%	2.3%	1.6%	0.014
Time to first exacerbation, days					
Mean (SD)	142.6 (98.9)	140.3 (95.1)	123.8 (82)	135.5 (92.5)	0.047
Median (P25 - P75)	132 (112–152)	130 (111–149)	116 (99–133)	130 (119–141)	
Mean (SD) nb of pneumonias	0.0 (0.2)	0.0 (0.2)	0.1 (0.3)	0.1 (0.2)	0.002
% Patients with pneumonia	3.4%	4.2%	6.9%	4.7%	0.041
Death (% patients)	9.8%	11.4%	12.4%	11.1%	0.238
Medication use (% patients)					
Oral corticosteroids	21.8%	23.5%	26.4%	25.3%	<0.001
Chronic use of oral corticosteroids	5.2%	7.5%	10.9%	8.1%	0.044
Systemic antibiotics	22.5%	25.7%	27.9%	23.8%	0.020
Beta-2 short-acting agonists	94.0%	92.0%	92.3%	92.9%	0.256
Xanthines	9.9%	8.7%	9.5%	9.4%	0.723
Leukotriene receptor antagonists	2.0%	2.1%	1.7%	1.9%	0.806
Home oxygen therapy	11.5%	11.4%	14.0%	12.3%	0.259
Duration of treatment (ICS), in months	10.3 (2.3)	10.5 (2.4)	10.1 (2.2)	10.4 (2.3)	0.748
Treatment changes	1.9 (0.2)	1.8 (0.2)	1.9 (0.2)	1.9 (0.2)	0.681

Note: Values expressed as percentage or mean.

Abbreviations: SD, standard deviation; p, statistical significance; P, percentile; IC, inhaled corticosteroids.

Table 3 Resource Use and Costs by Study Groups

Inhaled ICS Doses	Low	Medium	High	Total	p
Number of Patients, %	N=849	N=612	N=724	N=2185	
Resource use					
Medical visits, primary care	14.5 (9.1)	15.3 (10.1)	15.5 (10.9)	15.0 (10.0)	0.133
Laboratory tests	0.5 (0.9)	0.6 (1.0)	0.7 (1.1)	0.6 (1.0)	0.007
Conventional radiology	0.4 (1.2)	0.6 (1.7)	0.6 (1.6)	0.5 (1.5)	0.015
Complementary tests	0.4 (1.3)	0.4 (1.0)	0.5 (1.3)	0.4 (1.2)	0.466
Days of hospitalization	0.1 (0.3)	0.1 (0.4)	0.1 (0.4)	0.1 (0.3)	0.013
Medical visits, hospitals	3.5 (3.1)	3.8 (3.5)	3.9 (3.3)	3.7 (3.3)	0.030
Emergency visits, hospitals	2.7 (2.0)	3 (2.2)	3.0 (2.2)	2.9 (2.1)	0.001
Gross costs (€)					
Costs in primary care	1561 (536)	1569 (591)	1757 (631)	1628 (591)	<0.001
Medical visits	334 (210)	351 (232)	356 (250)	346 (230)	0.133
Laboratory tests	19 (32)	21 (34)	24 (37)	21 (34)	0.007
Conventional radiology	19 (58)	30 (78)	26 (76)	24 (70)	0.015
Complementary tests	36 (108)	34 (86)	41 (113)	37 (104)	0.466
Medications	1154 (397)	1133 (391)	1309 (435)	1199 (416)	0.001
Costs, specialized care	730 (985)	887 (1249)	914 (1229)	835 (1149)	0.003
Days of hospitalization	179 (701)	268 (907)	298 (908)	243 (835)	0.013
Medical visits	236 (212)	262 (235)	263 (222)	252 (222)	0.030
Emergency visits	315 (237)	357 (261)	354 (256)	339 (251)	0.001
Health costs	2291 (1313)	2456 (1674)	2670 (1670)	2.463 (1550)	<0.001
Corrected cost model (€)*				Difference	
Costs in primary care	1573	1558	1749	177	<0.001
95% CI	1522–1622	1497–1618	1695–1803		
Costs in specialized care	811	843	876	65	0.654
95% CI	717–904	729–956	774–977		
Total health costs	2383	2401	2625	242	0.024
95% CI	2256–2510	2247–2554	2488–2761		

Notes: Values expressed as mean. *ANCOVA model: Contrasts are based on pairwise comparisons between estimated marginal means.

Abbreviations: SD, standard deviation; p, statistical significance; CI, confidence interval; IC, inhaled corticosteroids.

differences were found according to ICS duration or treatment changes (ICS, LABA, LAMA) across the different cohorts analyzed, during the follow-up period (Tables 1 and 5). The incidence of pneumonia was similar between the two groups (3% vs.4.3%; $p=0.378$). For nEFP, the median time to first exacerbation was faster than for EFP (126 vs.160 days ($p=0.004$)). The annual mean PPPY healthcare cost with an EFP ICS was lower than that on nEFP ICS (€ 2090 vs € 2, 513 ($p<0.00$)) (difference: € -423/patient/year) (Table 6).

Joint Analysis

In the binary correlation model, age was principally associated with the time from diagnosis ($r=0.332$), comorbidity ($r=0.338$), mortality ($r=0.258$) and exacerbations

($r=0.177$). Comorbidity was associated with healthcare costs ($r=0.162$), exacerbations ($r=0.138$) and pneumonia ($r=0.075$). High doses of ICS were associated with FEV₁ ($r=0.178$), and healthcare costs with exacerbations ($r=0.792$) and pneumonia ($r=0.145$). nEFP ICS were associated with the number of exacerbations ($r=0.077$) and healthcare costs ($r=0.154$) ($p<0.03$). In the multiple linear regression analysis, healthcare costs were associated with the number of exacerbations ($\beta=0.807$), age ($\beta=0.178$), ICS particle size (nEFP: $\beta=0.121$), high doses of ICS ($\beta=0.042$), comorbidity ($\beta=0.041$) and FEV₁ ($\beta=-0.024$) ($p<0.02$ in all cases). The model determination coefficient was 65.2%. The number of exacerbations (during follow-up) was associated with FEV₁ ($\beta=-0.157$), age ($\beta=0.071$), comorbidity (Charlson: $\beta=0.050$) and ICS particle size

Table 4 Baseline Characteristics of Patients by Study Groups

Type of Particles	Extrafine	Non-Extrafine	p
Number of Patients, %	N=462 (31.6%)	N=999 (68.4%)	
Sociodemographic features			
Mean age, years	72.5 (11.5)	71.8 (11.7)	0.301
Range: 40–64 years	25.3%	25.9%	
65–74 years	26.8%	30.1%	
≥ 75 years	47.8%	43.9%	0.320
Sex (male)	81.4%	81.4%	0.999
Overall comorbidity			
Mean diagnoses	3.6 (1.8)	3.7 (1.9)	0.521
Mean Charlson Index	1.7 (1.5)	1.7 (1.5)	0.955
1	33.8%	30.2%	
2	19.7%	20.2%	
3+	24.9%	25.6%	0.367
Associated comorbidities			
Hypertension	62.3%	60.0%	0.387
Diabetes mellitus	27.1%	27.0%	0.991
Dyslipidaemia	55.4%	52.5%	0.292
Obesity	34.2%	33.3%	0.745
Active smoker	22.9%	23.2%	0.906
Ischemic heart disease	17.1%	18.2%	0.604
Cerebrovascular accident	11.7%	12.1%	0.817
Heart failure	24.9%	24.8%	0.978
Kidney failure	10.2%	11.1%	0.591
Depressive syndrome	13.9%	14.2%	0.854
Malign neoplasm	14.5%	14.0%	0.804
Asthma	14.7%	11.2%	0.058
COPD Severity			
GOLD II (moderate)	61.3%	62.2%	
GOLD III (severe)	37.0%	36.4%	
GOLD IV (very severe)	1.7%	1.4%	0.861
Other parameters/variables			
Time from diagnosis, years	16 (6.3)	15.4 (6.0)	0.083
BMI, kg/m ²	29.3 (5.2)	29 (5.1)	0.385
FEV ₁ , %	59.3 (13.3)	60.1 (13.4)	0.269
Blood eosinophils, cells/μL	181 (102.3)	185 (112.5)	0.678
Mean ICS dose	375.5 (121.5)	369.4 (121.4)	0.419

Note: Values expressed as percentage or mean.

Abbreviations: SD, standard deviation; p, statistical significance; GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index, kg/m²; FEV₁, forced expiratory volume in the first second.

(nEFP: $\beta=0.049$) ($p<0.02$). The model determination coefficient was 40.1%.

Discussion

The results of this study show that, in patients beginning triple therapy, an increase in the IC dose was not associated with a reduction in the number of exacerbations, while an increased risk of pneumonia was observed. Likewise, with equal severity of COPD, patients treated with EFP had lower rates of severe and moderate

Table 5 Description of Exacerbations and Pneumonia by ICS Particle Size Grouping

ICS Particle Size	Extrafine	Non-Extrafine	p
Number of Patients, %	N=462 (31.6%)	N=999 (68.4%)	
Follow-up period (one year)			
Total exacerbations, %	24.0%	30.4%	0.012
Mean (SD) number of exacerbations	0.5 (1.1)	0.5 (1.1)	0.172
% Patients with 0 exacerbation			
1	76.0%	69.6%	
2	12.8%	18.3%	
3+	5.4%	5.4%	
	5.8%	6.7%	0.048
Moderate exacerbations, %			
Mean (SD) number of exacerbations	23.6%	29.9%	0.048
% Patients with 0 exacerbation	0.4 (0.9)	0.5 (0.9)	0.165
1	76.4%	70.1%	
2	15.4%	21.0%	
3+	3.9%	3.9%	
	4.3%	5.0%	0.079
Severe exacerbations (hospitalization), %			
Mean (SD) number of exacerbations	6.5%	8.3%	0.078
% Patients with 0 exacerbation	0.1 (0.3)	0.1 (0.3)	0.268
1	93.5%	91.7%	
2	5.4%	7.0%	
	1.1%	1.3%	0.479
Time to first exacerbation			
Mean (SD)	164.6 (99)	133.4 (95.2)	0.004
Median (P25 - P75)	160 (138–182)	126 (114–138)	
% Patients with pneumonia	3.0%	4.3%	0.378
Mean (SD) nb of pneumonias	0.0 (0.2)	0.1 (0.2)	0.102
Deaths	9.7%	10.8%	0.534
Medication use			
Oral corticosteroids	26.4%	25.3%	0.413
Chronic oral corticosteroid use	7.9%	8.3%	0.685
Systemic antibiotics	21.2%	23.2%	0.647
Beta-2 short-acting agonists	95.2%	92.2%	0.032
Xanthines	9.7%	9.2%	0.746
Leukotriene receptor antagonists	2.2%	2.0%	0.839
Home oxygen therapy	11.3%	11.6%	0.843
Duration of treatment (ICS), in months	10.5 (2.2)	10.1 (2.3)	0.799
Treatment changes	1.8 (0.1)	1.9 (0.2)	0.691

Note: Values expressed as percentage or mean.

Abbreviations: SD, standard deviation; p, statistical significance; P, percentile.

exacerbations, resulting in lower health costs for the Spanish National Health System.

The total percentage of exacerbations increased according to the IC dose (low: 26.4%, medium: 28.7% and high: 30.4%), in line with the proportion of pneumonia (3.4%,

Table 6 Resource Use and Costs by ICS Particle Size Grouping

ICS Particle Size	Extrafine	Non-Extrafine	p
Number of Patients, %	N=462 (31.6%)	N=999 (68.4%)	
Resource use			
Medical visits, primary care	12.4 (8.5)	15.9 (9.8)	<0.001
Laboratory tests	0.5 (0.8)	0.6 (1.0)	0.075
Conventional radiology	0.2 (0.6)	0.6 (1.7)	<0.001
Complementary tests	0.4 (1.2)	0.4 (1.2)	0.396
Days of hospitalization	0.1 (0.3)	0.1 (0.3)	0.315
Medical visits, hospitals	2.8 (2.0)	4 (3.6)	<0.001
Emergency visits, hospitals	2.3 (1.2)	3.1 (2.4)	<0.001
Gross costs (€)			
Costs in primary care	1368 (500)	1655 (562)	<0.001
Medical visits	285 (196)	366 (224)	<0.001
Laboratory tests	18 (28)	21 (34)	0.075
Conventional radiology	9 (28)	30 (78)	<0.001
Complementary tests	32 (101)	36 (98)	0.396
Medications	1025 (382)	1200 (388)	<0.001
Costs, specialized care	643 (905)	867 (1180)	<0.001
Days of hospitalization	186 (743)	230 (817)	0.315
Medical visits	190 (136)	273 (247)	<0.001
Emergency visits	267 (137)	364 (280)	<0.001
Health costs	2011 (1185)	2522 (1568)	<0.001
Corrected cost model (€)*			
Costs in primary care	1376	1657	<0.001
95% CI	1313–1438	1614–1700	
Costs in specialized care	714	856	0.061
95% CI	591–837	771–939	
Health costs	2090	2513	<0.001
95% CI	1926–2252	2401–2624	

Notes: Values expressed in mean. *ANCOVA model: Contrasts are based on pairwise comparisons between estimated marginal means.

Abbreviations: SD, standard deviation; p, statistical significance; CI, confidence interval.

4.2% and 6.9%, respectively). The combination of IC + LAMA/LABA is controversial in the treatment of COPD.^{1,2,9,12} Some reviews show that triple therapy provides modest clinical benefits in the general COPD population, while achieving greater efficacy in patients with frequent exacerbations and eosinophilia (asthma-COPD phenotype).^{12,21,22} Conversely, adding a LAMA to an IC/LABA combination produces significant clinical benefits in COPD patients (dual bronchodilation).^{21,22} Most studies highlight the discrepancies between the guideline recommendations and the therapy used in clinical practice.^{9,12,21,22}

There is debate on the side effects, such as pneumonia and systemic adverse effects, of long-term IC use. Some reports suggest the safety profile of IC depends on the dose administered. Thus, there appear to be differences between the pathophysiological mechanisms related to the action of

IC, which are predominantly immunosuppressant at high doses and anti-inflammatory at lower doses. This may have practical effects, highlighting the value of low-dose IC in the treatment of COPD.²³ We found that patients who received high doses of IC vs low/moderate doses showed no reduction in exacerbations, although previous exacerbations were not considered, and these patients had more severe COPD. These results show the complexity of COPD therapy, especially in severe patients. As for the risk of pneumonia, our results seem to be in line with most studies, although this topic is also controversial. Cheng²⁴ concluded that high doses of IC had greater clinical effectiveness in COPD patients, with no higher incidence of pneumonia, and suggest that high-dose IC therapy may be appropriate in COPD patients. The Spanish PNEUMOCORT²⁵ study found that severe pneumonia and exacerbations were more common in patients with severe COPD and in patients receiving high doses of IC, results similar to ours.

The proportion of exacerbations was 24% in patients using EFP devices and 30.4% in those using nEFP devices. In the joint analysis (IC dose vs device type), exacerbations were indirectly related to the use of EFP devices (corrected by covariates). There is little reported evidence, but the TRILOGY¹⁰ and TRINITY²⁶ studies permit assessment of the effectiveness and safety of devices with EFP compared with other types of devices. Both studies show a slight reduction in exacerbations and the risk of pneumonia. The FORWARD²⁷ and TRIBUTE²⁸ studies also found a reduction in exacerbations, but no increase in the risk of pneumonia. A review by Scichilone²⁹ found that an inability to reach and treat peripheral airways may contribute to a lack of efficacy of inhaled treatments. The development of extrafine inhaled formulations allows a more uniform distribution of inhaled treatment throughout the respiratory tree. Better knowledge of the pathophysiology of the peripheral airways may help identify specific COPD phenotypes that would benefit from these treatments. Despite methodological discrepancies, our results may be in line with these contributions.

The mean cost per patient/year was higher in patients receiving high doses of IC compared with medium and low doses (€ 2625, € 2383 and € 2401, respectively). Likewise, costs were lower in patients with EFP devices (€ 2090) than in those using nEFP devices (€ 2513). These results are directly related to the proportion of exacerbations, especially severe exacerbations requiring hospitalization. Reviews by Press³⁰ and Ehteshami-Afshar³¹ highlighted

the wide methodological differences in the studies analysed and concluded that reports consistently show that better disease control reduces COPD costs and that there is a growing need for economic studies based on the latest guideline recommendations. Our results are difficult to compare since we have found no similar studies in the literature search. Most studies conclude that: a) the cost is related to COPD severity, b) rehospitalizations, emergency visits and medication were the most prominent cost components, and c) increasing health education can reduce COPD costs.^{32,33} In addition, COPD patients with eosinophil counts of ≥ 220 cells/ μL are more likely to have had moderate or severe exacerbations, implying higher costs.³⁴ Allowing for methodological limitations, our results seem to be in line with the available literature.

Our study has some limitations, principally those typical of retrospective studies, which are related to the categorization of COPD severity, the possible classification bias of patients and the limitations in the measurement of variables, attributable to the information system. In this respect, the possible inaccuracy of diagnostic coding in the diagnosis of COPD and other comorbidities, the definition of exacerbation, or the absence of variables that could influence the final results (socioeconomic level, environmental/occupational exposure, evolution of the pharmacological dose prescribed, verification of the inhalation technique, therapeutic adherence and/or the differentiation of phenotypes), should be considered as limitations. Other unmeasured factors that might have influenced the results may include: a) the length of use of IC in triple therapy, b) the pharmacological characteristics of the drug combinations, and/or c) the combination of these in each device (IC/LAMA/LABA, IC/LABA + LAMA, LABA/LAMA + IC). In addition, based on the demand for medical care, non-disease factors may have influenced the results, such as access to health resources, comorbidity or patient specifics, which could cause worsening episodes not to be reported by the patient and therefore remain untreated. We cannot exclude an indication bias due to severity, but when we adjust for parameters related with severity it does not seem to be any relevant difference. Regarding the changes in medication, the modifications of the concomitant respiratory treatment were not considered either, due to the technical complexity (time period) that represented their quantification in the database. Unfortunately, a more detailed analysis by molecules was not possible due to the small sample size. However, this study reflects routine clinical practice, in which the degree of adherence to clinical practice guidelines is rather low. In fact, in clinical practice it is common that more than 50% of patients are taking the high

dose triple in GOLD, which is not in accordance with the (GOLD) guidelines.³⁵

In conclusion, triple therapy may be an appropriate option in many patients, with low doses of IC. Increased IC doses were not associated with a reduction in the number of exacerbations, while an increased risk of pneumonia was observed. Patients treated with extrafine particle devices had lower rates of severe and moderate exacerbations, resulting in lower health costs for the Spanish National Health System. These results should be replicated in other healthcare settings.

Abbreviations

ATC, Anatomical Therapeutic Chemical Classification System; COPD, Chronic obstructive pulmonary disease; FEV₁, Maximum expiratory volume in the first second; GOLD, Global Initiative for Obstructive Lung Disease; HCRU, Healthcare resource use; ICS, Inhaled corticosteroid; LABA, Long-acting beta-2 agonist; LAMA, Long-acting muscarinic antagonist; LABD, Long-acting bronchodilators; MMAD, Mass median aerodynamic diameter; SAMA, Short-acting muscarinic antagonist.

Funding

This study was funded by Chiesi España S.A.U.

Disclosure

ASM reports grants from Chiesi, outside the submitted work. FJdA reports grants from Sanofi-Pasteur, outside the submitted work. JLIA has received consulting or speaking fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GSK, Grifols, Menarini, Novartis, Orion, Pfizer, Sandoz and Teva. The authors report no other conflicts of interest in this work.

References

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease 2017 report. GOLD executive summary. *Am J Respir Crit Care Med.* 2017;195:557–582. doi:10.1164/rccm.201701-0218PP
2. Kiley JP, Gibbons GH. COPD national action plan: addressing a public health need together. *Chest.* 2017;152:698–699. doi:10.1016/j.chest.2017.08.1155
3. Blanco I, Diego I, Bueno P, et al. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. *Int J Chron Obstruct Pulmon Dis.* 2017;13:57–67. doi:10.2147/COPD.S150853
4. Alfageme I, de Lucas P, Ancochea J, et al. 10 years after EPISCAN: a new study on the prevalence of COPD in Spain -a summary of the EPISCAN II protocol. *Arch Bronconeumol.* 2019;55:38–47. doi:10.1016/j.arbres.2018.05.011

5. Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Ibáñez-Nolla J. The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice. *Lung*. 2014;192:505–518. doi:10.1007/s00408-014-9592-7
6. Miravittles M, Murio C, Guerrero T, Gisbert R; on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. *Chest*. 2003;123:784–791. doi:10.1378/chest.123.3.784
7. Sicras A, Huerta A, Navarro R, Ibáñez J. Use of resources and associated costs of chronic obstructive pulmonary disease exacerbations: A population based retrospective study. *Semergen*. 2014;40:189–197. doi:10.1016/j.semgerg.2013.10.002
8. Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the global strategy for the diagnosis, management and prevention of COPD; 2019. Available from: <http://goldcopd.org>. Accessed August 18, 2019.
9. Miravittles M, Soler-Cataluña JJ, Calle M, et al. Spanish guidelines for management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. pharmacological treatment of stable phase. *Arch Bronconeumol*. 2017;53:324–335. doi:10.1016/j.arbres.2017.03.018
10. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β_2 -agonist therapy for chronic obstructive pulmonary disease (TRIOLOGY): a double-blind, parallel group, randomised controlled trial. *Lancet*. 2016;388:963–973. doi:10.1016/S0140-6736(16)31354-X
11. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy in patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2017;196:438–446. doi:10.1164/rccm.201703-0449OC
12. Alcázar Navarrete B, Casanova C, Miravittles M, de Lucas P, Riesco JA, Rodríguez González-Moro JM; Working Group. “Consensus document on the appropriate use of inhaled corticosteroids in COPD”. Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease”: a consensus document. *Arch Bronconeumol*. 2015;51:193–198. doi:10.1016/j.arbres.2014.11.001
13. Magnussen H, Disse B, Rodriguez-Roisin R, et al. WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *N Engl J Med*. 2014;371:1285–1294. doi:10.1056/NEJMoa1407154
14. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet Respir Med*. 2016;4:390–398. doi:10.1016/S2213-2600(16)00100-4
15. Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. *Lancet Respir Med*. 2014;2:497. doi:10.1016/S2213-2600(14)70103-1
16. Dhand R, Cavanaugh T, Skolnik N. COPD in primary care: key considerations for optimized management: considerations for optimal inhaler device selection in Chronic Obstructive Pulmonary Disease. *J Fam Pract*. 2018;67(2 Suppl):S19–S27.
17. Singh D, Corradi M, Spinola M, et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. *Int J Chron Obstruct Pulmon Dis*. 2017;12:2917–2928. doi:10.2147/COPD.S146822
18. Bassam M, Mayank V. Glucocorticoids - new recognition of our familiar friend. Chapter 23. Steroids in asthma: friend or foe; 2012. Available from: <https://www.intechopen.com/books/glucocorticoids-new-recognition-of-our-familiar-friend/steroids-in-asthma-friend-or-foe>. Accessed September 10, 2019.
19. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-8
20. World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD): disponible en; 2020. <http://www.who.int/classifications/atcddd/en/>. Consultado: enero.
21. Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. *Int J Chron Obstruct Pulmon Dis*. 2018;13:3971–3981. doi:10.2147/COPD.S185975
22. Cazzola M, Calzetta L, Rogliani P, Matera MG. Triple therapy versus dual bronchodilation and inhaled corticosteroids/long-acting β -agonists in COPD: accumulating evidence from network meta-analyses. *Pulm Ther*. 2019;5:117–126. doi:10.1007/s41030-019-00102-8
23. Izquierdo JL, Cosío BG. The dose of inhaled corticosteroids in patients with COPD: when less is better. *Int J Chron Obstruct Pulmon Dis*. 2018;13:3539–3547. doi:10.2147/COPD.S175047
24. Cheng SL, Su KC, Wang HC, Perng DW, Yang PC. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. *Drug Des Devel Ther*. 2014;8:601–607. doi:10.2147/DDDT.S63100
25. Morros R, Vedia C, Giner-Soriano M, Casellas A, Amado E, Baena JM; en representación de los investigadores del proyecto PNEUMOCORT. Community-acquired pneumonia in patients with chronic obstructive pulmonary disease treated with inhaled corticosteroids or other bronchodilators. Study PNEUMOCORT. *Aten Primaria*. 2019;51:333–340. doi:10.1016/j.aprim.2018.02.007
26. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet*. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-5
27. Wedzicha JA, Singh D, Vestbo J, et al. FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. *Respir Med*. 2014;108:1153–1162. doi:10.1016/j.rmed.2014.05.013
28. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet*. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
29. Scichilone N, Benfante A, Morandi L, Bellini F, Papi A. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. *Patient Relat Outcome Meas*. 2014;5:153–162.
30. Press VG, Konetzka RT, White SR. Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program. *Curr Opin Pulm Med*. 2018;24:138–146. doi:10.1097/MCP.0000000000000454
31. Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. *Int J Tuberc Lung Dis*. 2016;20(1):11–23. doi:10.5588/ijtld.15.0472
32. Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2121–2129. doi:10.2147/COPD.S211854
33. Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review. *Int J Chron Obstruct Pulmon Dis*. 2020;15:439–460. doi:10.2147/COPD.S234942
34. Trudo F, Kallenbach L, Vasey J, et al. Clinical and economic burden of eosinophilic COPD in a large retrospective US cohort. *Int J Chron Obstruct Pulmon Dis*. 2019;14:2625–2637. doi:10.2147/COPD.S220009
35. Izquierdo JL, Morena D, González Y, et al. Clinical management of COPD in a real-world setting. A big data analysis. *Arch Bronconeumol*. 2020;S0300-2896(20)30012-0. doi:10.1016/j.arbres.2019.12.025.

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>